Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Mol Cancer Res. 2021 Jun 28;19(10):1622–1634. doi: 10.1158/1541-7786.MCR-21-0147

Fig. 7. Osimertinib-resistant cells possess elevated basal levels of PD-L1 (A and B), which are minimally modulated by osimertinib (C) and PD-L1 elevation occurs in EGFRm NSCLC tissues after relapse to EGFR-TKI treatment (D and E).

Fig. 7.

A, RNA-seq analyses show that PD-L1 mRNA expression in PC-9AR was significantly elevated in comparison with PC-9 cells (N = 3 for each cell lines). B and C, Whole-cell protein lysates were prepared from cell lines as indicated as comparable cell densities (B) or the cell lines treated with different concentrations of osimertinib for 16 h (C). Western blotting was used to detect PD-L1 in parental and osimertinib-resistant NSCLC cell lines. GAPDH was used as a loading control. D and E, PD-L1 expression was detected using immunohistochemical staining in 19 paired human NSCLC tissues (D). The representative images were shown (E).